Profile of tocilizumab and its potential in the treatment of giant cell arteritis
Susan Patricia Mollan,1,2 John Horsburgh,1 Bhaskar Dasgupta3 1Birmingham Neuro-Ophthalmology Unit, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Birmingham, 2Institute of Metabolism and Systems Research, University of Birmingham, 3Department of Rheumatology, Southen...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-01-01
|
Series: | Eye and Brain |
Subjects: | |
Online Access: | https://www.dovepress.com/profile-of-tocilizumab-and-its-potential-in-the-treatment-of-giant-cel-peer-reviewed-article-EB |
id |
doaj-3fe1447fd5094055ba849b076e5a6310 |
---|---|
record_format |
Article |
spelling |
doaj-3fe1447fd5094055ba849b076e5a63102020-11-25T00:45:37ZengDove Medical PressEye and Brain1179-27442018-01-01Volume 1011136504Profile of tocilizumab and its potential in the treatment of giant cell arteritisMollan SPHorsburgh JDasgupta BSusan Patricia Mollan,1,2 John Horsburgh,1 Bhaskar Dasgupta3 1Birmingham Neuro-Ophthalmology Unit, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Birmingham, 2Institute of Metabolism and Systems Research, University of Birmingham, 3Department of Rheumatology, Southend University Hospital, Southend-on-Sea, UK Abstract: Giant cell arteritis (GCA) remains a medical emergency due to the threat of permanent sight loss. High-dose glucocorticoids (GCs) are effective in inducing remission in the majority of patients, however, relapses are common which lengthen GC therapy. GC toxicity remains a major morbidity in this group of patients, and conventional steroid-sparing therapies have not yet shown enough of a clinical benefit to change the standard of care. As the understanding of the underlying immunopathophysiology of GCA has increased, positive clinical observations have been made with the use of IL-6 receptor inhibitor therapies, such as tocilizumab (TCZ). This has led to prospective randomized control trials that have highlighted the safety and efficacy of TCZ in both new-onset and relapsing GCA. Keywords: giant cell arteritis, temporal arteritis, Horton disease, interleukin-6, tocilizumab, treatmenthttps://www.dovepress.com/profile-of-tocilizumab-and-its-potential-in-the-treatment-of-giant-cel-peer-reviewed-article-EBGiant Cell ArteritisTemporal ArteritisHorton DiseaseInterleukin-6TocilizumabTreatment |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mollan SP Horsburgh J Dasgupta B |
spellingShingle |
Mollan SP Horsburgh J Dasgupta B Profile of tocilizumab and its potential in the treatment of giant cell arteritis Eye and Brain Giant Cell Arteritis Temporal Arteritis Horton Disease Interleukin-6 Tocilizumab Treatment |
author_facet |
Mollan SP Horsburgh J Dasgupta B |
author_sort |
Mollan SP |
title |
Profile of tocilizumab and its potential in the treatment of giant cell arteritis |
title_short |
Profile of tocilizumab and its potential in the treatment of giant cell arteritis |
title_full |
Profile of tocilizumab and its potential in the treatment of giant cell arteritis |
title_fullStr |
Profile of tocilizumab and its potential in the treatment of giant cell arteritis |
title_full_unstemmed |
Profile of tocilizumab and its potential in the treatment of giant cell arteritis |
title_sort |
profile of tocilizumab and its potential in the treatment of giant cell arteritis |
publisher |
Dove Medical Press |
series |
Eye and Brain |
issn |
1179-2744 |
publishDate |
2018-01-01 |
description |
Susan Patricia Mollan,1,2 John Horsburgh,1 Bhaskar Dasgupta3 1Birmingham Neuro-Ophthalmology Unit, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Birmingham, 2Institute of Metabolism and Systems Research, University of Birmingham, 3Department of Rheumatology, Southend University Hospital, Southend-on-Sea, UK Abstract: Giant cell arteritis (GCA) remains a medical emergency due to the threat of permanent sight loss. High-dose glucocorticoids (GCs) are effective in inducing remission in the majority of patients, however, relapses are common which lengthen GC therapy. GC toxicity remains a major morbidity in this group of patients, and conventional steroid-sparing therapies have not yet shown enough of a clinical benefit to change the standard of care. As the understanding of the underlying immunopathophysiology of GCA has increased, positive clinical observations have been made with the use of IL-6 receptor inhibitor therapies, such as tocilizumab (TCZ). This has led to prospective randomized control trials that have highlighted the safety and efficacy of TCZ in both new-onset and relapsing GCA. Keywords: giant cell arteritis, temporal arteritis, Horton disease, interleukin-6, tocilizumab, treatment |
topic |
Giant Cell Arteritis Temporal Arteritis Horton Disease Interleukin-6 Tocilizumab Treatment |
url |
https://www.dovepress.com/profile-of-tocilizumab-and-its-potential-in-the-treatment-of-giant-cel-peer-reviewed-article-EB |
work_keys_str_mv |
AT mollansp profileoftocilizumabanditspotentialinthetreatmentofgiantcellarteritis AT horsburghj profileoftocilizumabanditspotentialinthetreatmentofgiantcellarteritis AT dasguptab profileoftocilizumabanditspotentialinthetreatmentofgiantcellarteritis |
_version_ |
1725269169287462912 |